Tempus AI (NASDAQ:TEM) CFO Sells $1,578,780.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 26,313 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer owned 106,024 shares in the company, valued at approximately $6,361,440. This trade represents a 19.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Tuesday, August 18th, James William Rogers sold 22,529 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total transaction of $1,117,663.69.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Price Performance

NASDAQ TEM opened at $72.69 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a fifty day simple moving average of $52.93 and a 200 day simple moving average of $51.36. The company has a market cap of $13.12 billion, a P/E ratio of -50.48 and a beta of 3.58. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the business posted ($0.22) EPS. On average, sell-side analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in TEM. Vanguard Group Inc. grew its position in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after buying an additional 817,014 shares in the last quarter. ARK Investment Management LLC raised its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. lifted its position in shares of Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares during the period. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TEM. Freedom Capital upgraded Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Wolfe Research assumed coverage on Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and a consensus target price of $65.69.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.